Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship (NCT04548193) | Clinical Trial Compass
CompletedPhase 1
Behavioral Dietary Intervention for the Improvement of Bladder Cancer Survivorship
United States49 participantsStarted 2021-04-05
Plain-language summary
This phase I trial investigates how well a healthy eating program works in improving outcomes in patients with bladder cancer. The behavioral dietary program consists of educational materials, live phone calls, and interactive voice response phone messages. Participating in the healthy eating program may improve eating habits and/or reduce the risk of bladder cancer from coming back.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* CANCER PATIENT: Age 18 years old or older (no upper limit)
* CANCER PATIENT: English speaking
* CANCER PATIENT: Diagnosed with stage Tis, Ta, or T1 bladder cancer
* CANCER PATIENT: Resides in the Western New York catchment area
* CANCER PATIENT: Did not receive a partial or radical cystectomy
* CANCER PATIENT: Does not have a prior cancer diagnosis within 12 months of their bladder cancer diagnosis
* CANCER PATIENT: Does not have a subsequent more advanced bladder cancer diagnosis
* CANCER PATIENT: For Roswell Park Cancer Registry only: Bladder cancer diagnosed 2016-2018, 2019-current
* CANCER PATIENT: Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.
* PHYSICIAN: English speaking
* PHYSICIAN: Physician in a clinic located in the catchment area
* PHYSICIAN: Currently treats bladder cancer patients
Exclusion Criteria:
* CANCER PATIENT: Participants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier
* CANCER PATIENT: Participants with known brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that wou…